Enhanced Antitumor Efficacy of 4-1BB-Based CD19 CAR-T Cells in Treating B-ALL

In a significant clinical study conducted by the Lu Daopei Hospital and Lu Daopei Institute of Hematology, researchers have found that 4-1BB-based CD19 CAR-T cells offer a promising alternative to traditional CD28-based CAR-T cells for treating relapsed or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). This study, involving rigorous pre-clinical and exploratory clinical investigations, showed that 4-1BB CAR-T cells not only provide a higher antitumor efficacy but also exhibit a longer persistence in patients compared to their CD28 counterparts.

The Lu Daopei Hospital's research team meticulously compared the performance of these two CAR-T cell types. They discovered that, under the same manufacturing process, 4-1BB CAR-T cells had a more potent antitumor effect at lower doses and caused fewer severe adverse events than CD28 CAR-T cells. The study's results indicate that 4-1BB-based CAR-T therapy might offer a more effective and safer treatment option for patients suffering from r/r B-ALL .

These findings underscore the commitment of the Lu Daopei Hospital to advancing hematology and immunotherapy, offering hope to patients who have not responded to conventional treatments. The study, which followed stringent ethical standards and received approval from the Lu Daopei Hospital Ethics Committee, emphasizes the hospital's role in leading innovative research in CAR-T cell therapies .

With this breakthrough, the Lu Daopei Institute of Hematology continues to pioneer new frontiers in medical research, providing cutting-edge treatment options and improving patient outcomes. This advancement is a testament to the dedication and expertise of the Lu Daopei Hospital's medical and research teams.